Surprisingly, understanding the critical roles of sphingolipid signaling in complement biology could be a potential therapeutic strategy for cancer immunotherapy, since the complement components C3/C3a/C3aR and C5/C5a/C5aR signaling are now emerging as potential targets for cancer immunotherapy improvements [168,169,170,171]. This evidence concerns the gene C5AR1 and cancer.